FDA Clearance Tracker · P210022
Alinity m CMV
Last checked: Nov 19, 2026Latest source record: May 5, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 5, 2022
Approved (reclassified)
Time to decision
338 days
Received Jun 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P210022
- Device name
- Alinity m CMV
- Applicant
- Abbott Molecular, Inc.
- Applicant location
- Des Plaines, IL
- Received
- Jun 1, 2021
- Decided
- May 5, 2022
- Decision
- Approved (reclassified)
- Supplements
- 12 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3180
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for Alinity m CMV. Alinity m CMV AMP KitThe Alinity m CMV assay is an in vitro polymerase chain reaction (PCR) assay for use with the automated Alinity m System to quantitate cytomegalovirus (CMV) DNA in human EDTA plasma. The Alinity m CMV assay is intended for use as an aid in the management of Hematopoietic Stem Cell Transplant and Solid Organ Transplant patients who are undergoing anti-cytomegalovirus therapy. The Alinity m CMV assay can be used to assess virological response to anti-cytomegalovirus therapy. The results from the Alinity m CMV test must be interpreted within the context of all relevant clinical and laboratory findings. The Alinity m CMV test is not intended as a screening test for the presence of CMV DNA in blood or blood products.Alinity m CTRL KitThe Alinity m CMV controls are for validity determination of the quantitative Alinity m CMV assay on the automated Alinity m System. These controls are intended to be used with the Alinity m CMV assay; refer to the assay package insert for additional information.Alinity m CAL KitThe Alinity m CMV calibrators are for calibration for the Alinity m CMV assay on the automated Alinity m System when used for the quantitative determination of CMV DNA. The calibrators are intended to be used with the Alinity m CMV assay; refer to the assay package insert for additional information.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Molecular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
- Alinity m HR HPVPMA supplement
P230003-S006 · Decided Sep 10, 2025 · 264 days after receipt · Panel Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
K243489 · Decided Jul 28, 2025 · 258 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.